ICD code T44.1X4A – Cholinergic agonist poisoning, undetermined intent

Key takeaways

T44.1X4A is a billable ICD-10-CM code for direct-acting cholinergic agonist poisoning when the record documents that intent cannot be determined.

When the record simply doesn’t state intent, the guidelines direct coders to accidental intent (T44.1X1A) instead.

The 7th character A covers every encounter during active treatment, including a transfer from the ED to the ICU.

Poisoning codes are sequenced first, followed by manifestation codes. No separate external cause code is required, because T44.1X4A already captures the drug and the intent.

Claims management software like Pabau captures companion manifestation codes at the point of documentation, which cuts T44.1X4A denials.

ICD-10 code T44.1X4A: Definition, billable status, and code hierarchy

ICD-10 code T44.1X4A is the fully specified, billable terminal code for poisoning by other parasympathomimetics (cholinergic agonists), undetermined intent, initial encounter. Coders assign it only when the record states that the intent behind the poisoning cannot be determined. Every character carries a specific clinical meaning that payers validate at claim adjudication, as the table below shows. Per the CDC/NCHS ICD-10-CM official code tool, T44.1X4A is valid and billable for FY2025 and FY2026.

Note that T44.1X4 without the 7th character is a non-billable parent code. Claims submitted with the truncated form will reject at the clearinghouse. Only T44.1X4A, T44.1X4D, or T44.1X4S are valid for submission.

Drugs classified under T44.1 cholinergic agonists

T44.1 covers direct-acting cholinergic agonists, also called muscarinic agonists or parasympathomimetics. These are drugs that bind directly to cholinergic receptors, as opposed to anticholinesterase agents that prevent acetylcholine breakdown.

According to the CMS ICD-10-CM Tabular List, T44.1 includes the following drug classes and examples:

• Pilocarpine (Salagen, Isopto Carpine) – used for glaucoma and dry-mouth management in Sjogren’s syndrome
• Bethanechol (Urecholine) – used for urinary retention and postoperative bladder atony
• Cevimeline (Evoxac) – used for dry-mouth in Sjogren’s syndrome
• Carbachol – ophthalmic cholinergic agent
• Other direct-acting muscarinic receptor agonists

What T44.1 does NOT include: Anticholinesterase agents (neostigmine, physostigmine, donepezil, rivastigmine) are classified under T44.0, not T44.1. Autonomic ganglionic blockers fall under T44.2. Beta-adrenergic blockers belong to T44.7. Confusing these categories is a common coding error that puts the wrong drug category on the claim and leads to denials.

Inclusions, exclusions, and T44 code boundaries

Understanding where T44.1X4A starts and stops prevents miscoding across the T44 family. The Excludes1 and Excludes2 notes in the Tabular List are binding.

Accurate boundary identification matters because coders sometimes encounter patients on combination regimens. A patient on both bethanechol and a cholinesterase inhibitor who experiences toxicity requires separate code analysis for each drug involved. The guidelines direct coders to report each drug individually unless a combination code exists.

Understanding “undetermined intent” in ICD-10 poisoning codes

“Undetermined intent” applies when the medical record provides no clinical basis to decide whether the poisoning was accidental, intentional self-harm, or the result of assault. Per the ICD-10-CM Official Guidelines Section I.C.19.e, it is coded only when the documentation specifically states that the intent cannot be determined.

When the intent is simply unknown or unspecified, the guidelines direct coders to code it as accidental. The flow below shows how the two questions a coder asks lead to each intent character.

Selecting T44.1X4A when documentation supports accidental intent creates compliance exposure. Payers cross-reference emergency department notes, toxicology reports, and nursing assessments during audits.

T44.1X4A vs adjacent codes: Avoiding common confusion

Most coding errors within the T44.1X family involve confusing intent characters or episode suffixes. The table below maps every sibling code so coders can verify selection before submitting. The AAPC Codify ICD-10-CM lookup provides current descriptor text for each.

The 7th character “A”: Initial encounter rules for T44.1X4A

The 7th character “A” means the patient is receiving active treatment for the cholinergic poisoning. It does not mean this is literally the first time they have been seen. A patient transferred from the ED to the ICU on day three of treatment still carries “A” if active treatment continues. The character changes only when the care context changes.

• A (initial encounter): Active treatment for the poisoning is ongoing. Includes ED visits, inpatient admission, and active outpatient management of the toxic episode.
• D (subsequent encounter): Routine follow-up care after the active treatment phase. The patient is recovering, not receiving active intervention for the poisoning itself.
• S (sequela): A late effect or complication that persists after the acute episode has resolved. The sequela condition becomes the principal diagnosis; T44.1X4S is sequenced after it.

Switching prematurely to “D” during an active inpatient stay is a common audit finding. The ICD-10-CM Official Guidelines Section I.C.19.a confirm that “A” applies through the entirety of the active treatment encounter, regardless of visit count.

Companion codes and sequencing rules for T44.1X4A

T44.1X4A rarely travels alone on a claim. ICD-10-CM Official Guidelines Section I.C.19.e require the poisoning code to be sequenced as the principal diagnosis, followed by codes for its manifestations. Codes in categories T36-T65 are combination codes that already include the substance and the intent, so no additional external cause code is required.

Codes to report, in order of sequencing:

1. T44.1X4A as principal diagnosis – always first, regardless of how many other conditions are present
2. Manifestation codes – report any specific signs or complications documented: Bradycardia (R00.1), excessive salivation (K11.7), bronchospasm (J98.01), miosis, urinary incontinence (R32), and GI cramping as appropriate
3. No separate external cause code – T44.1X4A already captures the cholinergic drug and the undetermined intent. Section I.C.19.e confirms that poisoning codes need no additional external cause code
4. Optional Y92, Y93, and Y99 codes – place of occurrence (Y92), activity (Y93), and external cause status (Y99) may be reported as secondary data. They are not required nationally, so add them only where a state mandate or a specific payer policy asks for them

A clearinghouse that validates companion code requirements catches a missing manifestation code before the payer sees it. It also flags a truncated parent code or an incomplete code set before the claim leaves the practice.

Documentation requirements to support T44.1X4A

Coders cannot assign ICD-10 code T44.1X4A without specific clinical elements in the medical record. Payers audit these claims against toxicology results and nursing notes, and missing elements found after payment trigger recoupment.

• Drug identification: The specific drug or drug class must be documented. “Cholinergic drug exposure” alone is insufficient. The record needs the drug name, such as bethanechol or pilocarpine
• Undetermined intent basis: The physician or clinician must document why intent cannot be determined. A statement such as “circumstances of ingestion unclear” or “patient unable to provide history; collateral unavailable” supports the selection
• Clinical signs of cholinergic toxidrome: Documented SLUDGE/DUMBELS findings link the symptom cluster to the drug class. These include salivation, lacrimation, urination, defecation, GI distress, emesis, diaphoresis, miosis, and bradycardia
• Encounter type: The documentation must support an initial encounter (active treatment), not a follow-up
• Toxicology results: Where available, a toxicology screen identifying the cholinergic agent strengthens medical necessity and supports coding specificity

Practices using error-checking claims software tied to clinical documentation catch these omissions while the chart is still open. The fix happens before the claim is built, so the denial never arrives.

Payer requirements and pre-authorization considerations

Medicare and Medicaid adjudicate T44.1X4A under standard poisoning rules. Commercial payer requirements vary, and some trigger additional review for undetermined-intent poisoning claims, particularly when the clinical setting is outpatient rather than emergency or inpatient.

• Medicare (inpatient): T44.1X4A as principal diagnosis drives DRG assignment. Manifestation codes for cardiac or respiratory complications elevate the DRG weight and affect reimbursement substantially
• Medicare (outpatient): APC assignment applies. Medicare does not require an external cause code with T44.1X4A. Outpatient edits focus instead on a valid, fully specified code and documentation that supports the undetermined intent
• Medicaid (state-dependent): Some state Medicaid programs require toxicology documentation before paying undetermined-intent poisoning claims. Coders should check each state’s Medicaid policy, because coverage rules vary from state to state
• Commercial payers: Undetermined intent can flag for clinical review when the record does not include a toxicology screen or a physician attestation. Prior authorization is rarely required for the poisoning encounter itself but may be triggered for extended inpatient stays or specific antidote treatments

Real-time eligibility verification before the encounter reduces the risk of submitting to an ineligible payer or missing secondary coverage. Pabau’s integration with Claim.MD runs real-time eligibility checks at over 400 US payers. It also supports the CMS-1500 and 837P claim formats that T44.1X4A billing uses.

Common claim denial reasons for T44.1X4A

Denial patterns for T44.1X4A are predictable. Five errors recur across these claims, and each is preventable with a structured pre-submission review. Pabau’s guide to denial codes in billing explains the claim adjustment reason codes (CARCs) that usually accompany these rejections.

• Wrong drug category: T44.1X4A assigned to an anticholinesterase such as neostigmine or donepezil, which belongs in T44.0 instead. The code no longer matches the medication in the record, and the mismatch surfaces on review or audit
• Wrong intent character: Using T44.1X4A when physician documentation clearly describes an accidental ingestion. This produces a coding-documentation mismatch that triggers medical necessity denial on audit
• Non-billable parent code submitted: Submitting T44.1X4 (without the 7th character) instead of T44.1X4A. The truncated form is non-billable and will reject immediately
• Missing manifestation codes: Payers expect manifestation codes when the clinical record documents complications. An inpatient claim with documented bradycardia and bronchospasm that carries only T44.1X4A looks clinically incomplete
• 7th character mismatch for setting: Using “A” on a follow-up visit where active treatment has already concluded, or “D” on an initial acute encounter. Payers cross-reference the place-of-service against the encounter suffix

Running a clean claim review on every T44.1X4A claim catches most of these errors before submission. The pro tip below turns that review into a monthly routine.

Clinical presentation of cholinergic agonist poisoning

Recognizing the cholinergic toxidrome lets coders check that the documented drug class matches the code selected. The SLUDGE/DUMBELS mnemonics describe the classic presentation that emergency toxicology notes record, and coders will meet them when assigning T44.1X4A.

Each documented sign or symptom that meets the threshold of a separately identifiable condition should carry its own manifestation code alongside T44.1X4A. This completeness signals clinical severity to the payer and is particularly important for inpatient DRG optimization. Undercoded complications on T44.1X4A inpatient claims regularly result in lower DRG weights. That can mean thousands of dollars in unrealized reimbursement per case.

How Pabau keeps T44.1X4A claims clean from chart to payer

Without a check at the point of documentation, a missing manifestation code or the wrong intent character usually surfaces as a denial. By then the encounter is weeks old, and fixing it means chasing the physician for an addendum.

Pabau’s claims management tools validate ICD-10 code combinations before submission, so an incomplete companion code set is flagged while the chart is still open. Claims then route through Claim.MD, Pabau’s US clearinghouse integration, which catches a truncated parent code before the 837P file goes out.

Electronic remittance advice comes back into the same system. Your billing team can see which poisoning claims paid and which need attention without logging in to a separate portal.

Stop cholinergic poisoning claims from denying on arrival

Pabau’s claims management tools validate ICD-10 code combinations, flag incomplete companion code sets, and route clean claims through Claim.MD before they reach the payer. See how it works for your practice.

Book a demo

Conclusion

T44.1X4A holds up on audit only when the chart says, in the clinician’s own words, that intent cannot be determined. If that statement is missing, query the physician or code accidental intent before the claim goes out.

From there, pair the code with a manifestation code for each documented sign, and keep the 7th character at A until active treatment ends. Build those checks into your pre-submission review and the denial patterns above become rare exceptions.

Book a demo to see how Pabau flags missing companion codes on poisoning claims before they reach the payer.

Continue your research

Need guidance on medical billing compliance for poison and toxicology claims? Medical billing compliance requirements covers the audit triggers and documentation standards that govern T36-T65 poisoning claims.

Confused about how denials are categorized after a T44.1X4A rejection? Denial management in healthcare explains how to read CARC denial codes and build a systematic appeals process.

Want to understand how 837P claim files carry ICD-10 codes to payers? 837 file format guide explains loop and segment structure for diagnosis code submission.

Looking for a structured framework for superbill design that captures companion codes? Superbill guide covers how to build a superbill that captures all required companion codes at the point of care.

Frequently asked questions